Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session

BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in r/r MDSEncouraging survival; Median overall survival 13.4 months in 20 high and very high-risk r/r MDS patients treated with bexmarilimab + …
Jetzt den vollständigen Artikel lesen